CMNDNasdaqPharmaceutical PreparationsFiscal year ends October 31
Clearmind Medicine Inc.
Financials through Q3 FY2026, quarter ended Jul 31, 2026
$6.00−0.26 (-4.15%)
Close on Oct 19, 2026
- Market cap
- $9.49M
- P/E (TTM)
- –
- Dividend yield
- –
Clearmind Medicine statistics
Financials through Jul 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Market Cap | $948.46K | $166.30M |
| Enterprise Value | -$11.09M | $88.19M |
Income (trailing twelve months)
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Pretax Income | -$3.79M | -$14.34M |
| EPS (Diluted) | -$30.35 | -$0.83 |
Balance sheet
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $12.04M | $61.43M |
| Net Cash (Debt) | $12.04M | $15.35M |
| Net Cash Per Share | $76.14 | $0.66 |
| Working Capital | $12.77M | $76.81M |
Financial position
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Current Ratio | 4.31 | 3.34 |
| Quick Ratio | 3.12 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Operating Cash Flow | -$4.73M | -$12.35M |
Efficiency
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Employee Count | 2 | 74 |
Shares
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Shares Outstanding | 158,076 | 58,127,000 |
| Shares Change (YoY) | 64.0% | 10.9% |
Taxes
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Income Tax | $70.45K | $79.87K |
Scores
| Measure | Clearmind Medicine | Industry median |
|---|---|---|
| Altman Z-Score | -1.82 | -0.22 |
Calculated by StockData from Clearmind Medicine's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.